Testicular Cancer Research

The Department of Urology at Indiana University School of Medicine is one of the world’s largest centers for the management of patients with testicular cancer. The surgical approach to the disease was pioneered at IU School of Medicine several decades ago and modifications have continued over time to improve patient care and outcomes. Through continued collaboration with the medical oncology, thoracic and general surgery divisions, faculty physicians are able to provide a comprehensive approach to patient care. Their research in testicular cancer is focused on lowering morbidity and improving patient outcomes.

Active Research

Researchers are currently collecting biospecimens to validate a new potential marker for germ cell tumors, micro RNA 371. This is a promising new biomarker in this population that may hold predictive characteristics. This is currently being evaluated in patients with clinical stage I and advanced disease.

Past Publications

Cary C, Masterson TA, Bihrle R, et al: Contemporary trends in postchemotherapy retroperitoneal lymph node dissection: Additional procedures and perioperative complications. Urol Oncol 2015; 33: 389.e15–21.

Testicular Cancer Research

Active Research

Biospecimen Collection

Improving Postoperative Pain and Length of Stay

Retroperitoneal Lymph Node Dissection for Clinical Stage I Testicular Cancer

Studying Testis Cancer Subpopulations

Surgery in Early Metastatic Seminoma

Understanding Pulmonary and Operative Morbidity

Past Publications

Contemporary Trends in Postchemotherapy Retroperitoneal Lymph Node Dissection

Long-Term Survival of Good-Risk Germ Cell Tumor Patients After Postchemotherapy Retroperitoneal Lymph Node Dissection

Modified Retroperitoneal Lymph Node Dissection for Post-Chemotherapy Residual Tumour A Long-Term Update

Multidisciplinary Clinic Approach Improves Overall Survival Outcomes of Patients with Metastatic Germ-Cell Tumors

Outcomes of Postchemotherapy Retroperitoneal Lymph Node Dissection Following High-Dose Chemotherapy with Stem Cell Transplantation

Risk of Recurrence for Clinical Stage I and II Patients with Teratoma Only at Primary Retroperitoneal Lymph Node Dissection

The Impact of Bleomycin on Retroperitoneal Histology at Post-Chemotherapy Retroperitoneal Lymph Node Dissection of Good Risk Germ Cell Tumors

Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation An International Collaboration